A Werner1, M Jäger, H Schmitz, R Krauspe. 1. Orthopädische Klinik, Universitätsklinikum Düsseldorf, Germany. werner@med.uni-duesseldorf.de
Abstract
BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of acute lymphoblastic leukemia (ALL) and other malignancies during childhood, avascular osteonecrosis appears in up to 30 % of the patients. Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young patients again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. PATIENTS: Three hips and eleven knee joints in 8 patients (4 male, 4 female) were operated on for symptomatic ON and/or osteochondral defects (OCD) after chemotherapy. Four of the patients underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all patients were satisfied with the functional results after the last follow up with pain free walking for a minimum of 60 minutes. No night pain was reported. One patient complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and OCD after chemotherapy should be the reduction of pain and preservation of the joint to bypass the risks of joint replacement in young patients, although total joint replacement may become indicated in endstage degeneration of the involved joint.
BACKGROUND: As a complication of chemotherapy/corticosteroids for the treatment of acute lymphoblastic leukemia (ALL) and other malignancies during childhood, avascular osteonecrosis appears in up to 30 % of the patients. Weight-bearing joints are involved in over 90 % of the cases. Total joint replacement is often necessary to restore function. Yet, endoprostheses in young patients again bare the risk of later complications and the need for several revision surgeries. In this report, joint preserving surgical strategies will be discussed. PATIENTS: Three hips and eleven knee joints in 8 patients (4 male, 4 female) were operated on for symptomatic ON and/or osteochondral defects (OCD) after chemotherapy. Four of the patients underwent surgery in more than one joint. The average age at the time of surgery was 18 years (range 14 - 26). The procedures included retrograde drilling (core decompression), bone grafting, implantation of collagen sponges with autologous bone marrow aspirate, osteochondral autograft transplantation and transplantation of periosteal flaps. Two hip joints underwent total joint replacement. Average follow up was 25 months. RESULTS: After an average follow up of 2 years, all patients were satisfied with the functional results after the last follow up with pain free walking for a minimum of 60 minutes. No night pain was reported. One patient complained about intermittent periods of dysaesthesia around the bone harvest area at the iliac crest. CONCLUSIONS: The aim of surgery for ON and OCD after chemotherapy should be the reduction of pain and preservation of the joint to bypass the risks of joint replacement in young patients, although total joint replacement may become indicated in endstage degeneration of the involved joint.
Authors: Deborah French; Leo H Hamilton; Leonard A Mattano; Harland N Sather; Meenakshi Devidas; James B Nachman; Mary V Relling Journal: Blood Date: 2008-02-19 Impact factor: 22.113
Authors: Lynda M Vrooman; Kristen E Stevenson; Jeffrey G Supko; Jane O'Brien; Suzanne E Dahlberg; Barbara L Asselin; Uma H Athale; Luis A Clavell; Kara M Kelly; Jeffery L Kutok; Caroline Laverdière; Steven E Lipshultz; Bruno Michon; Marshall Schorin; Mary V Relling; Harvey J Cohen; Donna S Neuberg; Stephen E Sallan; Lewis B Silverman Journal: J Clin Oncol Date: 2013-01-28 Impact factor: 44.544
Authors: Paivi Maria Miettunen; Lucie Lafay-Cousin; Gregory M T Guilcher; Alberto Nettel-Aguirre; Vijay Moorjani Journal: Clin Orthop Relat Res Date: 2012-09-25 Impact factor: 4.176
Authors: Mallorie B Heneghan; Susan R Rheingold; Yimei Li; Alix E Seif; Yuan-Shung Huang; Lisa McLeod; Lawrence Wells; Brian T Fisher; Richard Aplenc Journal: Clin Lymphoma Myeloma Leuk Date: 2016-01-04
Authors: Shanaz M Daneshdoost; Jad M El Abiad; Kathy J Ruble; Lynne C Jones; Janet L Crane; Carol D Morris; Adam S Levin Journal: J Pediatr Hematol Oncol Date: 2021-04-01 Impact factor: 1.289